\
&
Contact us
\
&
Contact us
This was 7 months ago
LocationKraków, Poland
This event is organised under the Polish Presidency of the Council, and focuses on the future of European health and pharmaceutical sector Discussions regarding strategies of Healthcare, Med-Tech&Digital Health and Bio-Pharma will be held in break-out sessions. The third part of the conference will focus on strategies to bridge the gap between the current status and the desired future, outlining specific actions for research and innovation.
Details can be found on the conference website https://lifescience4eu.eu
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
